Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL.
Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC) and advanced melanoma: Phase 1 KEYNOTE-029 study
Advertisement